The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
How AI can improve prognostication and transplant decisions in MDS
Matteo Della Porta, MD, IRCCS Humanitas Research Hospital, Milan, Italy, discusses the potential of artificial intelligence (AI) to improve prognostication and clinical decision-making in myelodysplastic syndromes (MDS). Prof. Della Porta highlights AI-based clinical decision support systems for optimizing transplantation timing, alongside emerging models that incorporate clonal evolution and longitudinal molecular data to refine risk stratification. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
